Clinical Trials
11 trialsNCT05169658 2026-05-13
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Completed
NCT03322865 2026-05-06
Obinutuzumab in Marginal Zone Lymphoma
University of Ulm
Phase 2 Active not recruiting
NCT06793189 2026-03-24
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Phase 2 Recruiting
NCT05783596 2026-03-16
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06504940 2026-02-27
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT04883437 2026-02-09
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
Phase 2 Recruiting
NCT06566807 2024-08-22
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Huai'an First People's Hospital
Phase 2 Recruiting
NCT06513234 2024-07-22
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06454968 2024-06-18
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05846750 2023-07-19
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03276468 2023-01-10
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
Phase 2 Completed